

Date: 6th February, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLTLD

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Unaudited Financial Results

With reference to the captioned subject, we enclose herewith Newspaper cuttings of Extract of Unaudited Financial Results for the quarter and nine months period ended 31st December, 2023, published in 'Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 6th February, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited


Manisha Saraf

Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2019PLC081123

Regd. Office: Alembic Road, Vadodra - 390 002

Tel: 0222-9837308

Email: apl.investors@alembic.co.inWebsite: www.alembicpharmaceuticals.com

**Extract of Statement of Consolidated Unaudited Financial Results for
the quarter and nine months period ended 31st December, 2023**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2023	31.12.2022	31.03.2023
	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations	1,838.57	1,508.02	5,652.92
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary Items)	184.58	154.48	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary Items)	184.58	154.48	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary Items)	158.45	121.92	341.59
Total Comprehensive Income for the period	181.49	124.24	358.36
Equity Share Capital	38.31	38.31	38.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	8.78	6.25	17.48
Research and Development Expenses	114.48	156.89	721.84

Notes:

1.	Standard details	Quarter Ended		Year Ended
		31.12.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Audited)
	Income from Operations	1,588.29	1,310.21	5,146.80
	Profit before Tax	258.70	144.31	346.58
	Profit After Tax	233.24	119.13	346.73
	Research and Development Expenses	113.75	143.62	689.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

541

Chirayz Amin

Chairman and CEO

Place : Vadodra

Date : 5th February, 2024



ALEMBIC PHARMACEUTICALS LIMITED

CIN: L34300GJ2010PLC001120
 Regd. Office: Alembic Road, Vadodra - 390 003
 Tel: 022-4537300
 Email: api.investors@alembic.co.in
 Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter and nine months period ended 31st December, 2023

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2023	31.12.2022	31.03.2023
	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations	1,890.82	1,589.82	5,652.83
Net Profit for the period (before Tax, Exceptional and/or Extraordinary Items)	184.58	154.49	354.99
Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	184.58	154.49	354.99
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/or Extraordinary Items)	180.45	121.92	341.89
Total Comprehensive Income for the period	181.40	124.94	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	9.18	6.20	17.48
Research and Development Expenses	114.48	158.85	321.94

Notes:

1. Standalone details	Quarter Ended		Year Ended
	31.12.2023	31.12.2022	31.03.2023
	(Unaudited)	(Unaudited)	(Audited)
Income from Operations	1,898.39	1,310.21	5,148.98
Profit Before Tax	358.76	144.31	345.83
Profit After Tax	333.24	119.13	348.73
Research and Development Expenses	113.75	149.82	698.29

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.secdia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited
 Sd/-

Place : Vadodra
 Date : 7th February, 2024

Chirag Amin
 Chairman and CEO

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-6637300

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter and nine months period ended 31st December, 2023

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2023	31.12.2022	31.03.2023
	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations	1,630.57	1,509.02	5,652.62
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	184.58	154.49	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	184.58	154.49	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	180.45	121.92	341.99
Total Comprehensive Income for the period	181.49	124.94	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	9.18	6.20	17.40
Research and Development Expenses	114.48	156.89	721.84

Notes:

1. Standalone details	Quarter Ended		Year Ended
	31.12.2023	31.12.2022	31.03.2023
	(Unaudited)	(Unaudited)	(Audited)
Income from Operations	1,588.39	1,310.21	5,149.00
Profit Before Tax	256.70	144.31	345.93
Profit After Tax	233.24	119.13	346.73
Research and Development Expenses	113.75	149.02	699.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited
Sd/-

Place : Vadodara

Chirayu Amin

Date : 5th February, 2024

Chairman and CEO